Is Savaysa already dead?

Quote






Anonymous said:
It's kind of hard to sell a drug with a massive black box warning about normal patients and almost zero MM access. Seriously, why would a doctor bother with Savaysa and the potential headaches when X and E are so easy to write? And both have better indications. Sell harder? Yeah, that will work.
Click to expand...

Agree. If my mom or dad was going to be prescribed this drug class...Savaysa would be my last choice for them out of the NOAC's. So as sales person I can't get behind this drug a 100%. The results right now and respones from the doctors on the drug speak for themselves.
 






A doctor asked me that question at a lunch when we were comparing Savaysa to all the other NOAC's. We had all the PI's out...and I could not disagree with him. As sales person, I want to sell but I would not want anyone I care about on this medication over the others.
 






Anonymous said:
It's dead because u haven't sold anything relevant in 10 years. Take the skirt off and actually challenge your customers rather than complaining. The days of benicar are gone so read your modules and figure out a way to actually do some work. Seriously the people who bitch and moan need to go so we can get some hungry reps who want to work in this company. The fact that u would post such a comment proves that u suck and need to find another gig.
Click to expand...

"Challenge your customers". Hmmm. Challenge them to what? Maybe we should do broad swords and "engage" our customers in some sort of a duel. Yes, a duel! Maybe foils or Sabres? I'm thinking perhaps a duel with pistols! Challenge your customers and always hold them accountable!
 












I believe that we can win, I believe that we can win, I believe that we can win, lol!!!!!!! Also, no hard feelings about that layoff right? Hey, did everyone get those $200 Nike gift cards I got you?! You're welcome.
 


















Savaysa is expected to make 200 million by 2019. Welchol was bringing in 600 million. How ironic one of the selling point for Savaysa is 1 pill once a day. P.S DSI recently sold it's shares in SunPharma. Money is running low.
 






Anonymous said:
Savaysa is expected to make 200 million by 2019. Welchol was bringing in 600 million. How ironic one of the selling point for Savaysa is 1 pill once a day. P.S DSI recently sold it's shares in SunPharma. Money is running low.
Click to expand...

No true. Got rid of Sun because company wanted to stay away from the generic business. Savaysa just got approved in Europe with better label.
 












Anonymous said:
No true. Got rid of Sun because company wanted to stay away from the generic business. Savaysa just got approved in Europe with better label.
Click to expand...

How do you know they want to stay away from the generic business? And how is the label different in Europe on Savaysa? If you could just copy and paste the links that would be great, because I'm interested.
 




































maybe it is because they have yet to recruit and train for live speaker programs. So many of the docs in our area laugh at us when Janssen & Pfizer are having programs all around us. If Daiichi thinks this docs are going to take our word for the safety & efficacy - they have underestimated the customer. It looks like we have plateaued and those scripts represent the pity scripts we initially got for our "relationships". Now that we have exhausted the relationships, there is nowhere else to go but down, unless they get some programs going and "webinars" don't count as a program. So pathetic
 


















Top Bottom
Back
Quote